Cellceutix Corporation Welcomes Dr. Stephen T. Sonis to Its Scientific Advisory Board
08 mars 2016 13h23 HE
|
Cellceutix
BEVERLY, MA--(Marketwired - March 08, 2016) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
Cellceutix Completes Dosing in Phase 2 Trial of Prurisol for Chronic Psoriasis, Top-Line Data Anticipated in May
01 mars 2016 09h30 HE
|
Cellceutix
BEVERLY, MA--(Marketwired - March 01, 2016) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
Cellceutix Submits Special Protocol Assessment Request to FDA for Phase 3 Clinical Trial of Brilacidin for ABSSSI
26 févr. 2016 08h00 HE
|
Cellceutix
BEVERLY, MA--(Marketwired - February 26, 2016) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
Assay Results From Cellceutix Phase 1 Clinical Trial of Kevetrin for Cancer Show Increased p21 Expression in 67.5% of Evaluable Patients
22 févr. 2016 09h30 HE
|
Cellceutix
BEVERLY, MA--(Marketwired - February 22, 2016) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
Cellceutix Completes Clinical Trial of Kevetrin for Advanced Solid Tumors
16 févr. 2016 09h30 HE
|
Cellceutix
BEVERLY, MA--(Marketwired - February 16, 2016) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
Cellceutix Files Motion to Dismiss Complaint Filed by The Rosen Law Firm
12 févr. 2016 08h00 HE
|
Cellceutix
BEVERLY, MA--(Marketwired - February 12, 2016) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
Cellceutix Meets With FDA for Phase 2 Clinical Trial of Kevetrin for Ovarian Cancer
10 févr. 2016 14h22 HE
|
Cellceutix
BEVERLY, MA--(Marketwired - February 10, 2016) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
Cellceutix to Submit Special Protocol Assessment Request to FDA for Phase 3 Clinical Study of Antibiotic Brilacidin for ABSSSI
09 févr. 2016 09h25 HE
|
Cellceutix
BEVERLY, MA--(Marketwired - February 09, 2016) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
Cellceutix Phase 2 Trial of New Oral Treatment for Psoriasis Nearing Completion
25 janv. 2016 10h00 HE
|
Cellceutix
BEVERLY, MA--(Marketwired - January 25, 2016) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
Cellceutix Releases Data Used in Receiving FDA Orphan Drug Designation of Kevetrin for Pancreatic Cancer
22 janv. 2016 12h03 HE
|
Cellceutix
BEVERLY, MA--(Marketwired - January 22, 2016) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...